A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML)
Abbas Raza(University of Vermont), Aaron D. Schimmer(University of Toronto), Harry P. Erba(Michigan Center for Translational Pathology), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Thomas H. Carter(University of Iowa), Naomi Galili(Columbia University Irving Medical Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), M. S. Berger(Duke University), David F. Claxton(The University of Texas MD Anderson Cancer Center)
Cited by 8
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k